Merus (NASDAQ:MRUS) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.
A number of other research firms have also recently weighed in on MRUS. Wedbush restated an “outperform” rating and issued a $34.00 price target (up previously from $26.00) on shares of Merus in a report on Friday, July 27th. ValuEngine cut Merus from a “buy” rating to a “hold” rating in a report on Monday, September 24th. Finally, Zacks Investment Research upgraded Merus from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Thursday, September 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Merus presently has an average rating of “Hold” and a consensus price target of $28.00.
MRUS opened at $15.00 on Thursday. The company has a market capitalization of $310.41 million, a P/E ratio of -3.50 and a beta of -0.21. Merus has a 1-year low of $12.00 and a 1-year high of $26.74.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.